Medical management of motor manifestations of Huntington disease

Area of Science:

• Neurology
• Movement Disorders
• Huntington's Disease Management

Background:

• Huntington disease (HD) presents with complex motor and non-motor symptoms.
• Chorea and dystonia are prevalent movement disorders in HD, impacting quality of life.
• Dysphagia and comorbidities significantly influence treatment decisions and tolerance.

Purpose of the Study:

• To outline principles for managing motor and movement disorders in Huntington disease.
• To review current treatment options, considering limited evidence and expert consensus.
• To emphasize a multidisciplinary approach integrating medical and non-medical interventions.

Main Methods:

• Review of existing literature and clinical guidelines for HD motor management.
• Assessment of treatment efficacy based on available evidence (Class 1, expert opinion, off-label use).
• Consideration of the broader HD phenotype beyond motor symptoms in treatment planning.

Main Results:

• Tetrabenazine is the only agent with Class 1 evidence for chorea in HD.
• Many treatments are guided by expert opinion, reflecting a wider range of HD symptoms than typically studied.
• Non-medical interventions and multidisciplinary assessments are crucial, especially later in the disease.
• Medication review is essential as HD progresses.

Conclusions:

• Effective Huntington disease motor disorder management necessitates a comprehensive strategy addressing all symptoms.
• The evidence base for HD motor treatments is sparse, highlighting the importance of expert clinical judgment.
• Integrated care involving medical, non-medical, and multidisciplinary approaches is vital for optimal patient outcomes.